The standard chemotherapy for ovarian cancer includes the combination of paclitaxel and a platinum compound. Comparing carboplatin /paclitaxel with cisplatin/paclitaxel, it has been found that substitution of the analog carboplatin for cisplatin in this combination may improve the toxicity profile. Objectives: 1) To grade toxicity (according to WHO toxicity scale) and to compare the toxicity profile of cisplatin/paclitaxel versus carboplatin/paclitaxel in advanced epithelial ovarian carcinoma. 2) To compare the performance status of patients receiving these regimens. 3) To assess the clinical response rate based on CA 125 criteria. Methodology: 80 patients diagnosed with advanced epithelial ovarian cancer (stage III and stage IV), were recruited for the study and were divided into two groups of 40 each. One group received cisplatin-paclitaxel and the other received carboplatin-paclitaxel. All toxicities were graded according to WHO toxicity grading criteria. Response was assessed by CA 125 criteria, and patients categorized as responders or non responders based on whether raised serum CA 125 (pretreatment) values decreased by 50% during therapy. Results: Hematological toxicity namely anemia, leucopenia and thrombocytopenia were significantly more in patients treated with carboplatin. Nephrotoxicity, ototoxicity, neurotoxicity, nausea, vomiting and diarrhea were significantly more with cisplatin(p value __ampersandsignlt;0.01). Response rate was similar in both treatment arms-Cisplatin(57.5%) and Carboplatin(62.5%)(p value 0.648).